Core Viewpoint - The successful implantation of the "EVO+ICL(V5)" artificial lens at the Eye Hospital in Yongzhou marks a significant advancement in vision correction technology, particularly benefiting athletes like Gao Xiang who face challenges due to high myopia [1][9]. Group 1: Patient Experience and Needs - Gao Xiang, a key player in the Xiangchao championship team, struggled with severe myopia of approximately 800 degrees, which affected his performance on the field [3]. - The decision to undergo surgery was driven by the need for clear vision during training and competitions, as wearing contact lenses caused discomfort and impacted his performance [3][5]. Group 2: Technological Advancements - The "EVO+ICL(V5)" lens is recognized for its advantages such as non-invasive corneal procedures, strong reversibility, and a wide range of correction, making it a preferred choice for athletes [4]. - The V5 lens features an expanded optical zone of 6.1mm, enhancing night vision and reducing visual disturbances like glare and halos, which is crucial for athletes [4]. Group 3: Surgical Process and Expertise - Prior to the surgery, over 20 detailed eye examinations were conducted to assess Gao Xiang's eye condition, ensuring a personalized surgical plan was developed [5][7]. - Dr. Huang Haitao, with over 30 years of experience and nearly 20,000 surgeries performed, led the operation, emphasizing the importance of safety and tailored solutions for athletes [7]. Group 4: Post-Surgery Outcomes - Post-operative assessments showed Gao Xiang achieving a vision of 1.2 in the right eye and 1.0+ in the left eye, leading to a significant improvement in his visual clarity and overall training focus [7]. - Gao Xiang expressed high satisfaction with the surgery and the professional service provided by the Eye Hospital, highlighting the positive impact on his athletic performance [7]. Group 5: Industry Recognition - During the 14th "Caring for Myopia・Smile Forum," Aier Eye Hospital received dual recognition, with six hospitals becoming part of the "EVO+ ICL(V5) Clinical Research Alliance" and 14 experts recognized as initial clinical application specialists [9]. - The successful surgery of Gao Xiang not only showcases the technology's benefits for athletes but also reinforces Aier Eye Hospital's strength in the field of refractive surgery [9].

据中国经济网记者不完全统计，过去一年时间里，爱尔眼科及其下属医院2度被相关监管部门通报，4度 被处罚。 广西壮族自治区市场监督管理局公众号2025年1月14日公布了2024年度民生领域虚假违法广告典型案 例。其中案例3为贵港爱尔眼科医院有限公司广告违法案件。经查，贵港爱尔眼科医院有限公司利用网 络媒介发布广告，该医疗广告内容与《医疗广告审查证明》核准的广告成品样件内容不一致。2024年3 月，贵港市港北区市场监管局对当事人作出行政处罚。 中国经济网北京1月29日讯信用中国网站显示，横州爱尔眼科（300015）医院有限公司近期新增行政处 罚决定书(横卫医罚﹝2026﹞1号)。 横州爱尔眼科医院有限公司未经备案开展义诊活动，该行为违反了《医疗机构管理条例》第二十三条的 规定，依据《医疗机构管理条例》第四十三条第二款的规定，横州市卫生健康局给予罚款人民币捌仟元 整(8000.00)的行政处罚。 信网23日报道《丽水爱尔眼科重复收费造成医疗保障基金损失被罚7.7万余元》显示，近日，丽水爱尔 眼科医院有限公司因分解收费、重复收费等造成医疗保障基金损失，被罚77543.75元，并退回违规行为 造成的基金损失48346.7 ...

Core Viewpoint - He Eye Hospital (301103) expects a net profit attributable to shareholders of 24 million to 36 million for 2025, representing a year-on-year growth of 187.60% to 231.40% [1] Group 1: Performance Improvement - The company has achieved a turnaround from loss to profit during the reporting period, driven by business structure optimization, effective cost control, and the disposal of inefficient assets [1] - Significant enhancement in profitability is attributed to the continuous optimization of the business structure, with a focus on high-margin refractive and optical businesses [1] Group 2: Cost and Efficiency Management - The company has implemented refined operational management, achieving cost reduction and efficiency improvement through centralized procurement optimization, supply chain efficiency enhancement, and digital operations [1] - These measures have contributed to the overall improvement in profitability [1] Group 3: Asset Optimization - The company has actively integrated, adjusted, or divested certain business units that have long-term poor performance or weak strategic synergy, further optimizing asset allocation efficiency [1]

Core Viewpoint - The company is expected to turn a profit in 2025, reversing previous losses due to optimized business structure, effective cost control, and the clearing of inefficient assets [1][2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a turnaround from loss to profit, indicating a positive shift in financial performance [1]. Group 2: Reasons for Performance Change - Continuous optimization of the business structure has driven growth, particularly in high-margin refractive and optical businesses [2]. - Significant results from cost and expense management have been achieved through refined operational management, centralized procurement, and enhanced supply chain efficiency [2]. - The company has actively integrated, adjusted, or divested underperforming business units to improve asset allocation efficiency [2]. Group 3: Additional Information - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an accounting firm [3]. - Final financial data will be disclosed in the company's 2025 annual report [3].

Core Viewpoint - Guangzheng Eye Hospital announced that its stock price experienced a cumulative deviation of over 20% on January 26 and January 27, 2026, which meets the criteria for abnormal stock fluctuations set by the Shenzhen Stock Exchange [1]. Group 1 - The stock price fluctuation occurred over two consecutive trading days [1].

Group 1 - The core point of the article is that He Eye Hospital has announced an expected net profit for the year 2025, projecting earnings between 24 million to 36 million yuan, a significant turnaround from a loss of 27.3982 million yuan in the same period last year [2] Group 2 - The company is forecasting a positive financial performance for 2025, indicating a recovery and growth potential in its operations [2] - The previous year's loss highlights the challenges faced by the company, making the projected profit a notable improvement [2] - This announcement may influence investor sentiment positively, as it suggests a shift towards profitability [2]

Group 1 - The company, Chaoju Eye Care (02219.HK), announced a share buyback on January 27, spending HKD 162,000 to repurchase 60,000 shares at a price range of HKD 2.69 to HKD 2.71 per share [1]

Group 1 - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan [1] - The company will spend HKD 162,000 to repurchase 60,000 shares [1]

Group 1 - The company, Chaoyue Eye Care (02219), announced a share buyback plan, intending to repurchase 60,000 shares at a cost of HKD 162,000 [1]

Core Viewpoint - He Eye Hospital has announced a positive earnings forecast for 2025, projecting a significant turnaround from previous losses to a net profit range of 24 million to 36 million yuan [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is between 24 million and 36 million yuan, compared to a loss of 27.3982 million yuan in the same period last year [1] - The forecasted net profit after deducting non-recurring gains and losses is estimated to be between 11 million and 16.5 million yuan, while the previous year's figure was a loss of 28.7877 million yuan [1]